List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
Proteins are often studied as static structures, yet they behave dynamically in living systems. Tiffanwy Klippel-Cooper of OmnigeniQ explains how physics-based modelling could help researchers better understand drug targets.
Experimental Parkinson’s drug PRI-101 has shown promising preclinical results, effectively targeting and disassembling toxic α-synuclein protein aggregates that drive neurodegeneration.
Dr Raminderpal Singh interviews Dr Jack Scannell on his six-week transformation from coding spectator to genomic data practitioner.
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.
ELRIG has announced the keynote speakers for its 2026 Advances in Cell-based Screening conference in Gothenburg, where scientists will gather to explore how human-first models, advanced cell biology and AI are changing the future of drug discovery.
A key player in brain communication and mood regulation, the pharmaceutical industry views the NMDAR as the central pillar for next-generation therapies for depression. Dirk Beher from FundaMental Pharma reveals new strategies for targeting this important receptor.
Scientists at the University of Cambridge have developed a light-powered method to modify complex drug molecules without toxic chemicals, enabling faster, cleaner and more efficient drug development.
A topical cream that activates the skin’s immune defences has been shown to suppress tumour growth in early models of cutaneous squamous cell carcinoma.
Automation is helping drug discovery teams screen faster, cut costs and run complex assays at scale – but its real value lies in what happens next.
Scientists at the University of Toronto have created long noncoding RNA outside living cells for the first time, a breakthrough that has already produced experimental anti-inflammatory molecules.
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
At World ADC London 2026, experts highlighted how advances in payload design, targeting strategies and AI-driven discovery are changing antibody–drug conjugate development.
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
